A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis

Neurogastroenterology and Motility

Volumn 25, Issue 2, 2013, Pages

  Ejskjaer, N ^a   Wo, J M ^b   Esfandyari, T ^c   Mazen Jamal, M ^d   Dimcevski, G ^e   Tarnow, L ^f   Malik, R A ^g   Hellstrom P M ^h   Mondou, E ⁱ   Quinn, J ⁱ   Rousseau, F ⁱ   Mccallum, R W ^j  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f STENO DIABETES CENTER   (Denmark)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ Tranzyme Pharma   (United States)

^j TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

Diabetes type 1; Diabetes type 2; Diabetic gastroparesis; Gastroparesis; Oral ghrelin receptor agonist

Indexed keywords

GHRELIN RECEPTOR; HEMOGLOBIN A1C; PLACEBO; SOMATOMEDIN C; TPZ 102; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIABETIC GASTROPARESIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SATIETY; SKIN ULCER; STOMACH EMPTYING; STOMACH PARESIS; SYMPTOM; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RECEPTORS, GHRELIN; YOUNG ADULT;

EID: 84872676054     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12064     Document Type: Article

References (28)

1. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum R. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term followup of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398-404.
2. Jung H, Choung R, Locke G et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009; 136: 1225-33.
3. Lyrenas E, EH O, Arvidsson UC, Orn T, Spjuth JH. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 1997; 20: 413-8.
4. Horowitz M, Harding P, Maddox A et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabeatologia 1989; 32: 151-9.
5. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002; 19: 177-94.
6. Parkman H, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol 2010; 6: 1-16.
7. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999; 60: 422-7.
8. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24: 1264-9.
9. Parkman HP, Camilleri M, Farrugia G et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil 2010; 22: 113-33.
10. Date Y, Kojima M, Hosoda H et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-61.
11. Fukuda H, Mizuta Y, Isomoto H et al. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 2004; 39: 1209-14.
12. Binn M, Albert C, Gougeon A et al. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides 2006; 27: 1603-6.
13. Murray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005; 54: 1693-8.
14. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22: 847-53.
15. Vestergaard ET, Hansen TK, Gormsen LC et al. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007; 292: E1829-36.
16. Ejskjaer N, Vestergaard ET, Hellstrom PM et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29: 1179-87.
17. Revicki DA, Rentz AM, Dubois D et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res 2004; 13: 833-44.
18. Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci 1994; 21: S3-7.
19. Shaw M, Dent J, Beebe T et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008; 6: 31-6.
20. Federal Drug Administration Guidance for industry irritable bowel syndrome - clinical evaluation of drugs for treatment, Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdf. May 2012.
21. Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003; 18: 141-50.
22. Shin A, Camilleri M, Busciglio I et al. Randomized controlled phase 1b study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2012; 35: 1-8 Sep 6 [Epub ahead of print].
23. Velanovich V. Difficulty in assessing quality of life outcomes in a fluctuating disease: a hypothesis based on gastroparesis. Gastroenterol Res Pract 2009; 2009: 396190.
24. Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113: 60-6.
25. Jones KL, Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentration influences postprandial fullness in IDDM. Daibetes Care 1997; 20: 1141-6.
26. Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999; 22: 339-44.
27. Merio R, Festa A, Bergmann H et al. Slow gastric emptying in type 1 diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care 1997; 20: 419-23.
28. Holzäpfel A, Festa A, Stacher-Janotta G et al. Gastric emptying in type II (non-insulin dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia 1999; 42: 1410-2.